{"id":"W2262699108","doi":"10.1200/jco.2007.25.18_suppl.7649","title":"IND.175: Phase I study of daily oral AZD2171, a vascular endothelial growth factor receptor inhibitor (VEGFRI), in combination with gemcitabine and cisplatin (G/C) in patients with advanced non-small cell lung cancer (ANSCLC): A study of the NCIC Clinical Trials Group","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital","funders":"","keywords":"Medicine; Gemcitabine; Toxicity; Adverse effect; Internal medicine; Pharmacokinetics; Dosing; Gastroenterology; Urology; Chemotherapy; Pharmacology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000673807,0.001207412,0.00122043,0.0005164162,0.0004677293,0.0006801478,0.0006840234,0.000955873,0.005147693],"category_scores_gemma":[0.0003886557,0.000434042,0.0007177243,0.000406208,0.00074086,0.0004078177,0.0002343853,0.001716091,0.001341303],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007725603,"about_ca_system_score_gemma":0.001325055,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001185585,"about_ca_topic_score_gemma":0.002765415,"domain_scores_codex":[0.9998108,0.00008030517,0.00001225826,0.0000292098,0.00002446954,0.00004298569],"domain_scores_gemma":[0.9997904,0.00003210189,0.00002867103,0.00001203738,0.0000105591,0.0001261441],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5893649,0.08165935,0.01496085,0.002181206,0.001846108,0.00128368,0.0004057792,0.004278338,0.0866879,0.001219746,0.02702493,0.1890872],"study_design_scores_gemma":[0.5976679,0.3690756,0.01556642,0.00005996026,0.0003734815,0.0005833423,0.00004766332,0.001451472,0.004696184,0.0002842955,0.01015131,0.00004223211],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9835024,0.003276548,0.0005795578,0.0006639166,0.0001843903,0.003092018,0.002777659,0.0001737607,0.005749677],"genre_scores_gemma":[0.9819111,0.002149076,0.001825578,0.001776461,0.0002371234,0.002525989,0.004285254,0.00002803644,0.005261277],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005147693,"threshold_uncertainty_score":0.01722074,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06008348037096114,"score_gpt":0.4673260500090812,"score_spread":0.4072425696381201,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}